Clinical Assay Development Services

Bring your assays to market faster. From design and development to manufacturing of high-quality IVD assays, our Clinical Assay Development Services (CADS) provide a seamless delivery pipeline. We provide you with a superior assay development service backed by rigorous quality control, proven technical expertise and our own trusted reagents and technologies.

With CADS, you will benefit from:

  • Accelerated time to market
  • Deep knowledge of core technologies
  • In-house control of supply chain and quality
  • Scientist-to-scientist collaboration
  • Range of development capabilities
  • Mature design control and documentation
Request a Conversation

Flexible Solutions and Comprehensive Support for Clinical Assay Development

Other assay development providers rely on outside resources to deliver your ideas, slowing progress and delaying critical workflows. Our Clinical Assay Development Services (CADS) combines proven expertise with adaptable technology to help you move from concept through manufacturing with confidence. Simplify with a single partner, from beginning to end. Learn more about our Immunoassay development options below.

Immunoassays
Modern immunoassay development requires speed, flexibility and compatibility with complex biological samples without compromising sensitivity or scalability. Through CADS, we offer a homogeneous immunoassay platform that is redefining immunoassays across performance, simplicity and scalability.

How Lumit® Flex Technology Works

Lumit® Flex is a bioluminescent immunoassay system that detects specific antigens or antibodies using a patented Add-Mix-Read process. The system employs two small peptide tags and a detection substrate that works as follows:

  1. Peptide α and Peptide β are attached to assay antibodies or antigens.
  2. When both peptides bind the same target, the peptide tags move into close proximity.
  3. The Detection Substrate reassembles into an active NanoLuc® luciferase, producing a light signal that directly reflects analyte concentration.

Learn More about our Lumit® Technology

18974ma2


Lumit® Flex System simplifies immunoassays with two small peptide tags and a detection protein.

Add-Mix-Read Workflow:
18977ma2
Lumit® Flex is an easy, no-wash, no multiple incubation workflow for automation-friendly analyte detection.
Flexible Formats

Single Samples

18978ma4
Flexible Formats: Lumit® Flex technology offers flexibility in sample type, analyte choice, assay format and workflow. It can be adapted to formats including point-of-care (POC) to high-throughput testing.

Low-to-Mid Throughputs

18979mb

High-Throughput

18980mb
Support At Every Step

We offer a uniquely comprehensive portfolio of technology development, manufacturing and logistics that enable us to support every step of your clinical assay development, from conception to delivery.

18973ma
Key Benefits

Faster results: Complete assays in as little as 5–90 minutes.

Simplified workflow: Homogeneous Add-Mix-Read design reduces manual steps and variability.

High sensitivity and dynamic range: Detect low-abundance targets with minimal background noise.

Easy integration: Works with standard luminescence-capable microplate readers—no new equipment required.

Consistent results: No washes or multiple incubation steps.

Scalable performance: Suitable for point-of-care to high-throughput applications.

Stable and reliable: Lyophilization-compatible, all-in-one format stable at room temperature.

Flexible formats: Performs even with difficult targets or challenging sample types, adaptable across sample types, analytes, assay formats, and workflows.

Lumit® Flex Publications

See how Lumit® Flex Technology is used in these peer-reviewed publications:

Kincaid, V. A. et al. (2022) Simple, Rapid Chemical Labeling and Screening of Antibodies with Luminescent Peptides. ACS Chem. Biol. 17, 8, 2179-2187.

Hall, M. P. et al (2021) Toward a Point-of-Need Bioluminescence-Based Immunoassay Utilizing a Complete Shelf-Stable Reagent. Anal. Chem. 93, 12, 5177-5184.

Torio, E. A. et al. (2022) Development of a rapid, simply, and sensitive point-of-care technology platform utilizing ternary NanoLuc. Front. Microbiol., Sec. Infectious Agents and Disease. 13.

Let's Partner to Develop Your Next Assay

Whether you have a project in mind or simply want to get more details about how our capabilities can meet your needs, we welcome the opportunity to develop your next assay.

Request a Conversation

Manufacturing Capabilities

With 40+ years of manufacturing experience and a track record of serving more than 100 global IVD companies, you can trust us to produce your assay. We offer manufacturing expertise in a variety of areas including:
  • Nucleic Acid Chemistry
  • Bioluminescence
  • Cell Manufacturing
  • Protein Purification
  • Fermentation
  • Custom Manufacturing
  • Amplification and Human Identify
  • cGMP Contract Manufacturing
primarymanufacturer
Manufacturing Infrastructure
cgmp

Our manufacturing infrastructure features:

  • Room to grow for future needs: over 450,000 square feet (41,000m2) of manufacturing space.
  • Strong relationships: Over half of our suppliers are located within 50 miles of our Madison, Wisconsin manufacturing facilities.
  • Deep knowledge: The average tenure of our manufacturing leaders is 15+ years.
  • Exemplary customer experience: surveyed customers have >99% satisfaction rate.
Quality and Support

Our rigorous quality system ensures we can develop, manufacture, test and deliver high-quality products around the world. Our global supply chain, product quality, design and quality documentation are managed in-house, providing you greater peace of mind.

To demonstrate our commitment to meeting industry standards, we maintain ISO certifications at all global manufacturing sites.

  • ISO 9001:2015 Provides general quality management system requirements
  • ISO13485:2016 Provides quality management system requirements for medical devices
  • ISO18385:2016 Minimizes the risk of human DNA contamination in products
  • MDSAP (Medical Device Single Audit Program)
    • ISO 13485:2016
    • Canada – Medical Device Regulations – Part 1 – SOR 98/282
    • USA – 21 CFR 820, 21 CFR 803, 21 CFR 806, 21 CFR 807 – Subparts A to D
iso-13485

Request a Consult

Whether you have a question about our Clinical Assay Development Services or are ready to get started, we are here to help.
Fill out the form below and a member of our CADS team will be in touch with you shortly.